Head-To-Head Analysis: SIGA Technologies (SIGA) vs. Sevion Therapeutics (SVON)

SIGA Technologies (OTCMKTS: SIGA) and Sevion Therapeutics (OTCMKTS:SVON) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Volatility & Risk

SIGA Technologies has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Sevion Therapeutics has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Valuation & Earnings

This table compares SIGA Technologies and Sevion Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SIGA Technologies $14.99 million 25.00 -$39.69 million ($0.53) -8.96
Sevion Therapeutics $80,000.00 209.85 -$5.79 million ($4.91) -0.06

Sevion Therapeutics has lower revenue, but higher earnings than SIGA Technologies. SIGA Technologies is trading at a lower price-to-earnings ratio than Sevion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for SIGA Technologies and Sevion Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SIGA Technologies 0 0 0 0 N/A
Sevion Therapeutics 0 0 0 0 N/A

Institutional & Insider Ownership

6.7% of SIGA Technologies shares are held by institutional investors. 4.7% of SIGA Technologies shares are held by insiders. Comparatively, 7.7% of Sevion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


This table compares SIGA Technologies and Sevion Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SIGA Technologies -201.85% N/A -23.22%
Sevion Therapeutics N/A -264.80% -81.73%


Sevion Therapeutics beats SIGA Technologies on 6 of the 11 factors compared between the two stocks.

SIGA Technologies Company Profile

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Sevion Therapeutics Company Profile

Eloxx Pharmaceuticals, Inc., formerly Sevion Therapeutics, Inc., is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company’s product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company’s antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply